AF
SPRO icon

Amalgamated Financial’s Spero Therapeutics SPRO Stock Holding History

Amalgamated Financial’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$34K Buy
+3,887
New +$39.8K ﹤0.01% 2581

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Amalgamated Financial's SPRO Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Spero Therapeutics (SPRO) in Q1 2022: 3,887 shares worth $34K. The stake represents ﹤0.01% of the portfolio and ranks #2581 among its holdings.

100 funds tracked by Wall St. Rank hold SPRO as of Q1 2022.

  • Amalgamated Financial held 3,887 shares of Spero Therapeutics worth $34K as of Q1 2022.
  • Spero Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Spero Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2581 holding.
  • 100 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.